However, optimal quantification of [18F]PI-2620 PET remains challenging due to low to moderate increases in tracer uptake in typical 4R tau-vulnerable subcortical regions compared to the 3/4R tauopathy AD, where cortical tau-PET increases are much stronger [15, 29]. The gene discussed is MAPT; the disease is tauopathy.